CompoAtlas

VISIOMINE

Food supplement declared in France, declaration No 2018-3-281, decision dated 8 March 2018

VISIOMINE is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
not provided
Food business operator placing the product on the market
PHYTOVIE
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
1 gélule par jour

Declaration 286993, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Vitis vinifera L.GraineExtrait sec aqueux60 mg
Vaccinium myrtillus L.FruitExtrait sec aqueux50 mg

Other active ingredients

NamePer day
Lutéinenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
Dioxyde de siliciumSiliciumpas de limite (données insuffisantes)no fixed dose
Acétate de D-alpha-tocophéryleVitamine E300 mg30 mg
Citrate de zincZinc25 mg15 mg

Additives

E463

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Vaccinium myrtillus L.
    Read the warning, when it applies and the studies cited

    BILBERRY - VACCINIUM MYRTILLUS - Buccal

    Route of administration: Buccal (Blumenthal et al. 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 30 January 2026

    BILBERRY - VACCINIUM MYRTILLUS - Oral

    Route of administration: Oral (Blumenthal et al. 2000)

    Cautions and warnings

    Condition of application: Relief of diarrhea.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Health Canada monograph dated 25 October 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2018. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line